{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:57:59Z","timestamp":1793141879549,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-53145-0","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T02:02:24Z","timestamp":1728871344000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5443-0802","authenticated-orcid":false,"given":"Manuel","family":"Rodrigues","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toulsie","family":"Ramtohul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Rampanou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Sandoval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6267-2353","authenticated-orcid":false,"given":"Alexandre","family":"Houy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8378-8432","authenticated-orcid":false,"given":"Vincent","family":"Servois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9ah","family":"Mailly-Giacchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2536-7680","authenticated-orcid":false,"given":"Gaelle","family":"Pierron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5754-5771","authenticated-orcid":false,"given":"Anne","family":"Vincent-Salomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Cassoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Dutriaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pracht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ryckewaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Emmanuel","family":"Kurtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Roman-Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Piperno-Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5932-8949","authenticated-orcid":false,"given":"Fran\u00e7ois-Cl\u00e9ment","family":"Bidard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8100-2272","authenticated-orcid":false,"given":"Marc-Henri","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9234-1002","authenticated-orcid":false,"given":"Shufang","family":"Renault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,14]]},"reference":[{"key":"53145_CR1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41572-020-0158-0","volume":"6","author":"MJ Jager","year":"2020","unstructured":"Jager, M. J. et al. Uveal melanoma. Nat. Rev. Dis. Prim. 6, 24 (2020).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"53145_CR2","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1093\/annonc\/mdz176","volume":"30","author":"L Khoja","year":"2019","unstructured":"Khoja, L. et al. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. Ann. Oncol. 30, 1370\u20131380 (2019).","journal-title":"Ann. Oncol."},{"key":"53145_CR3","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","volume":"389","author":"JC Hassel","year":"2023","unstructured":"Hassel, J. C. et al. Three-year overall survival with tebentafusp in metastatic uveal melanoma. N. Engl. J. Med 389, 2256\u20132266 (2023).","journal-title":"N. Engl. J. Med"},{"key":"53145_CR4","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"53145_CR5","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1038\/s41591-022-02015-7","volume":"28","author":"RD Carvajal","year":"2022","unstructured":"Carvajal, R. D. et al. Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial. Nat. Med. 28, 2364\u20132373 (2022).","journal-title":"Nat. Med"},{"key":"53145_CR6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11864-019-0667-9","volume":"20","author":"L Gerratana","year":"2019","unstructured":"Gerratana, L. et al. Emerging role of genomics and cell-free DNA in breast cancer. Curr. Treat. Options Oncol. 20, 68 (2019).","journal-title":"Curr. Treat. Options Oncol."},{"key":"53145_CR7","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41571-018-0074-3","volume":"15","author":"L Cabel","year":"2018","unstructured":"Cabel, L. et al. Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy. Nat. Rev. Clin. Oncol. 15, 639\u2013650 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"53145_CR8","doi-asserted-by":"publisher","first-page":"3934","DOI":"10.1158\/1078-0432.CCR-12-0309","volume":"18","author":"J Madic","year":"2012","unstructured":"Madic, J. et al. Pyrophosphorolysis-activated polymerization detects circulating tumor DNA in metastatic uveal melanoma. Clin. Cancer Res. 18, 3934\u20133941 (2012).","journal-title":"Clin. Cancer Res"},{"key":"53145_CR9","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/ijc.28436","volume":"134","author":"FC Bidard","year":"2014","unstructured":"Bidard, F. C. et al. Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma. Int J. Cancer 134, 1207\u20131213 (2014).","journal-title":"Int J. Cancer"},{"key":"53145_CR10","doi-asserted-by":"crossref","unstructured":"Park, J. J., et al. Circulating tumor DNA reflects uveal melanoma responses to protein kinase C inhibition. Cancers (Basel) 13, 1740 (2021).","DOI":"10.3390\/cancers13071740"},{"key":"53145_CR11","doi-asserted-by":"publisher","first-page":"S1210","DOI":"10.1016\/j.annonc.2021.08.1702","volume":"32","author":"AN Shoushtari","year":"2021","unstructured":"Shoushtari, A. N. et al. Early reduction in ctDNA, regardless of best RECIST response, is associated with overall survival (OS) on tebentafusp in previously treated metastatic uveal melanoma (mUM) patients. Ann. Oncol. 32, S1210 (2021).","journal-title":"Ann. Oncol."},{"key":"53145_CR12","doi-asserted-by":"publisher","first-page":"e827","DOI":"10.1097\/SLA.0000000000005822","volume":"278","author":"P Mariani","year":"2023","unstructured":"Mariani, P. et al. Circulating Tumor DNA as a prognostic factor in patients with resectable hepatic metastases of uveal melanoma. Ann. Surg. 278, e827\u2013e834 (2023).","journal-title":"Ann. Surg."},{"key":"53145_CR13","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","volume":"385","author":"P Nathan","year":"2021","unstructured":"Nathan, P. et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N. Engl. J. Med. 385, 1196\u20131206 (2021).","journal-title":"N. Engl. J. Med"},{"key":"53145_CR14","unstructured":"Cancer, A. J. C. o. In: AJCC Cancer Staging Manual (ed^(eds). 8th edn. Springer (2017)."},{"key":"53145_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/14737159.2018.1400384","volume":"18","author":"M Postel","year":"2018","unstructured":"Postel, M., Roosen, A., Laurent-Puig, P., Taly, V. & Wang-Renault, S. F. Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective. Expert Rev. Mol. Diagn. 18, 7\u201317 (2018).","journal-title":"Expert Rev. Mol. Diagn."},{"key":"53145_CR16","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1158\/2159-8290.CD-20-0047","volume":"10","author":"Q Zhang","year":"2020","unstructured":"Zhang, Q. et al. Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. Cancer Discov. 10, 1842\u20131853 (2020).","journal-title":"Cancer Discov."},{"key":"53145_CR17","doi-asserted-by":"publisher","first-page":"6212","DOI":"10.1158\/1078-0432.CCR-18-0386","volume":"24","author":"R Raja","year":"2018","unstructured":"Raja, R. et al. Early reduction in ctDNA predicts survival in patients with lung and bladder cancer treated with durvalumab. Clin. Cancer Res. 24, 6212\u20136222 (2018).","journal-title":"Clin. Cancer Res"},{"key":"53145_CR18","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1158\/1078-0432.CCR-17-1341","volume":"24","author":"SB Goldberg","year":"2018","unstructured":"Goldberg, S. B. et al. Early assessment of lung cancer immunotherapy response via circulating tumor DNA. Clin. Cancer Res. 24, 1872\u20131880 (2018).","journal-title":"Clin. Cancer Res"},{"key":"53145_CR19","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour, L. et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 18, e143\u2013e152 (2017).","journal-title":"Lancet Oncol."},{"key":"53145_CR20","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/j.molonc.2014.06.004","volume":"8","author":"N Amirouchene-Angelozzi","year":"2014","unstructured":"Amirouchene-Angelozzi, N. et al. Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target. Mol. Oncol. 8, 1508\u20131520 (2014).","journal-title":"Mol. Oncol."},{"key":"53145_CR21","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1023\/A:1018479011340","volume":"15","author":"PW Chen","year":"1997","unstructured":"Chen, P. W. et al. Expression of MAGE genes in ocular melanoma during progression from primary to metastatic disease. Clin. Exp. Metastasis 15, 509\u2013518 (1997).","journal-title":"Clin. Exp. Metastasis"},{"key":"53145_CR22","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/(SICI)1097-0215(19960503)66:3<380::AID-IJC19>3.0.CO;2-F","volume":"66","author":"GP Luyten","year":"1996","unstructured":"Luyten, G. P. et al. Establishment and characterization of primary and metastatic uveal melanoma cell Lines. Int J. Cancer 66, 380\u2013387 (1996).","journal-title":"Int J. Cancer"},{"key":"53145_CR23","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1373\/clinchem.2013.206375","volume":"59","author":"JF Huggett","year":"2013","unstructured":"Huggett, J. F. et al. The digital MIQE guidelines: minimum information for publication of quantitative digital PCR experiments. Clin. Chem. 59, 892\u2013902 (2013).","journal-title":"Clin. Chem."},{"key":"53145_CR24","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/clinchem\/hvaa125","volume":"66","author":"JF Huggett","year":"2020","unstructured":"d, M. G., Huggett, J. F. The digital MIQE guidelines update: minimum information for publication of quantitative digital PCR experiments for 2020. Clin. Chem. 66, 1012\u20131029 (2020).","journal-title":"Clin. Chem."},{"key":"53145_CR25","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1038\/s41388-020-1174-y","volume":"39","author":"E Jeannot","year":"2020","unstructured":"Jeannot, E. et al. A single droplet digital PCR for ESR1 activating mutations detection in plasma. Oncogene 39, 2987\u20132995 (2020).","journal-title":"Oncogene"},{"key":"53145_CR26","doi-asserted-by":"crossref","unstructured":"Zonta, E., et al. Multiplex detection of rare mutations by picoliter droplet based digital PCR: sensitivity and specificity considerations. PLoS One 11, e0159094 (2016).","DOI":"10.1371\/journal.pone.0159094"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-53145-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-53145-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-53145-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T09:03:32Z","timestamp":1729242212000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-53145-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,14]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["53145"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-53145-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,14]]},"assertion":[{"value":"5 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.R. reports personal fees for serving as an advisor from Merck Sharp & Dohme, AstraZeneca, GlaxoSmithKline, Immunocore; travel support from AstraZeneca; funds to his institution to support research from Merck Sharp & Dohme, Janssen-Cilag, Daiichi-Sankyo. F-C.B. received advisory board fees from Pfizer, AstraZeneca, Daiichi-Sankyo, Lilly, Novartis, Menarini, Caris Life Science, GE Healthcare, Exact Sciences, Gilead, Roche, SAGA Diagnostics; research support from AstraZeneca, Novartis, Pfizer, Prolynx, Merck KGAa, GE Healthcare, SAGA Diagnostics, Personalis; travel support from AstraZeneca, Novartis, Pfizer, Daiichi-Sankyo. A.V-S. received research grant from AstraZeneca, Daiichi-Sankyo, Ibex, Owkin, Primaa; travel support from AstraZeneca, Roche; conference fees from Daiichi-Sankyo, Exactsciences, Amgen; honoraria for conferences or lectures from AstraZeneca, Roche, MSD, Exactsciences; advisory board or consultant fees from Ibex, Primaa. M.P. received advisory board fees and travel support from AstraZeneca. J-E.K. reports personal fees for serving as an advisor from GlaxoSmithKline, Clovis Oncology, Tesaro, AstraZeneca, and Dragonfly Therapeutics; funds to his institution to support research from Merck Sharp & Dohme; travel support from Roche, PharmaMar, Tesaro. S.P-N reports personal fees for serving as an advisor from Immunocore and Pierre Fabre and travel support from Immunocore, Novartis. M-H.S. and S.R. received research support from Immunocore. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8851"}}